sulpiride has been researched along with Body Weight in 52 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine." | 9.12 | Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. ( De Hert, M; Mortimer, A; Peuskens, J, 2007) |
| "To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia." | 9.10 | A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 9.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| " Similarly, obesity induced by the neuroleptic drug sulpiride (SUL, 20 mg/kg/ip for 21 days) was prevented by AM only at the dose of 100 mg/kg." | 7.69 | Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. ( Alastre, T; Alternus, M; Araujo de Baptista, E; Baptista, T; Contreras, Q; de Quijada, M; Hernández, L; López, ME; Musseo, E; Páez, X; Teneud, L; Weiss, SR, 1997) |
| " First, the effect of lithium chloride (1, 2 and 4 mEq/kg IP for 21 days) on body weight was assessed in female and male rats." | 7.68 | Mechanism of the sex-dependent effect of lithium on body weight in rats. ( Baptista, T; Burguera, JL; Burguera, M; Hernandez, L; Murzi, E, 1991) |
| "Long-term intraperitoneal administration of sulpiride induced body weight increase in female but not in male rats." | 7.67 | Mechanism of the body weight increase induced by systemic sulpiride. ( Baptista, T; de Quijada, M; Hernandez, L; Paez, X; Parada, MA; Puig de Parada, M, 1989) |
| " We conducted a prospective, open study in schizophrenia patients in order to compare body weight and serum lipids during treatment with amisulpride, ziprasidone, clozapine or olanzapine over a period of 4 weeks." | 5.12 | Early changes of plasma lipids during treatment with atypical antipsychotics. ( Baumgartner, S; Ebenbichler, C; Edlinger, M; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Rettenbacher, MA, 2006) |
| " We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine." | 5.12 | Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. ( De Hert, M; Mortimer, A; Peuskens, J, 2007) |
| "To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia." | 5.10 | A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 5.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| " First, in preclinical experiments in female rats the estradiol antagonist/agonist drug tamoxifen or estradiol itself have been shown to completely prevent the obesity provoked by the AP sulpiride, and to induce an endocrine-metabolic milieu that seems to counteract AP-induced obesity." | 4.80 | Body weight gain induced by antipsychotic drugs: mechanisms and management. ( Baptista, T, 1999) |
| "Recent evidence suggests that methylphenidate HCl may be effective at limiting the frequency and the amount of binge eating." | 3.73 | Acute methylphenidate treatments reduce sucrose intake in restricted-fed bingeing rats. ( Bello, NT; Hajnal, A, 2006) |
| "Previous studies showed that the antipsychotic drugs (APDs) sulpiride (SUL) and risperidone (RIS) induced body weight gain (BWG), hyperphagia, and increased serum levels of leptin, prolactin and corticosterone in female rats." | 3.72 | Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. ( Baptista, T; Beaulieu, S; de Baptista, EA; Joober, R; Kin, NM; Lalonde, J; Plamondon, J; Richard, D, 2004) |
| " More recently our laboratory has reported that prenatal exposure to haloperidol (HAL), a neuroleptic which binds to and blocks dopamine receptor sites in the adult brain, permanently stunts body and brain growth when that exposure extends throughout postimplantation pregnancy." | 3.69 | Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms. ( Grafton, TF; Hansen, DK; Holson, RR; Webb, PJ, 1994) |
| "1 mg of domperidone/kg of body weight/d; and 3." | 3.69 | Efficacy of domperidone and sulpiride as treatments for fescue toxicosis in horses. ( Cross, DL; Kennedy, SW; Redmond, LM; Strickland, JR, 1994) |
| " Similarly, obesity induced by the neuroleptic drug sulpiride (SUL, 20 mg/kg/ip for 21 days) was prevented by AM only at the dose of 100 mg/kg." | 3.69 | Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. ( Alastre, T; Alternus, M; Araujo de Baptista, E; Baptista, T; Contreras, Q; de Quijada, M; Hernández, L; López, ME; Musseo, E; Páez, X; Teneud, L; Weiss, SR, 1997) |
| " First, the effect of lithium chloride (1, 2 and 4 mEq/kg IP for 21 days) on body weight was assessed in female and male rats." | 3.68 | Mechanism of the sex-dependent effect of lithium on body weight in rats. ( Baptista, T; Burguera, JL; Burguera, M; Hernandez, L; Murzi, E, 1991) |
| "Long term administration of the antipsychotic drugs thioridazine, trifluoperazine, haloperidol, and sulpiride increased body weight in rats." | 3.67 | Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? ( Baptista, T; Hernandez, L; Parada, M, 1987) |
| " A set of core outcomes to standardise infant weight and milk volume measurement is also needed, as well as a strong basis for the dose and dosage form used." | 2.66 | Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants. ( Foong, SC; Foong, WC; Ho, JJ; Marasco, LA; Ong, JH; Tan, ML, 2020) |
| " However, increased implantation loss was observed at 10 mg/kg or more, which was considered to be caused by the adverse effect of sulpiride on oocyte development." | 1.35 | Collaborative work on evaluation of ovarian toxicity. 17) Two- or four-week repeated-dose studies and fertility study of sulpiride in female rats. ( Adachi, T; Inoue, Y; Ishii, S; Mutai, M; Okada, M; Sugimoto, J; Ube, M; Uno, Y, 2009) |
| "Corticosterone treatment resulted in marked adrenal atrophy and flattening of the glucocorticoid rhythm as measured by repeated blood sampling." | 1.35 | Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder. ( Fairchild, G; Gartside, SE; Ingram, CD; McQuade, R; Minton, GO; Young, AH, 2009) |
| "Antipsychotic treatment during pregnancy is indicated when risk of drug exposure to the fetus is outweighed by the untreated psychosis in the mother." | 1.35 | Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats. ( Hao, Y; Liu, H; Liu, Z; Lu, XH; Ouyang, X; Xu, L; Zuo, J, 2008) |
| "Acute and chronic administration of vigabatrin, a selective inactivator of GABA-T, suppresses haloperidol-induced dyskinesias at low doses without preventing the enhancement of striatal dopamine D2 receptor density or the development of vacuous chewing movements." | 1.29 | Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin. ( Elands, J; Gobaille, S; Grauffel, C; Knödgen, B; Moran, P; Sarhan, S; Seiler, N; van den Buuse, M, 1995) |
| " This study examined the effect of chronic administration of haloperidol, clozapine, sulpiride and metoclopramide on stereotypy and locomotor activity elicited by direct injection of dopamine in to the striatum or nucleus accumbens, respectively." | 1.28 | Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. ( Davis, KL; Guerin, JJ; Halperin, R, 1989) |
| " Chronic administration of sulpiride does not induce identical changes in striatal dopamine function to those caused by haloperidol." | 1.27 | Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. ( Fleminger, S; Hall, MD; Jenner, P; Kilpatrick, G; Mann, S; Marsden, CD; Rupniak, NM, 1984) |
| "When sulpiride was withdrawn, migraine frequently recurred." | 1.26 | [Sulpiride in the prevention of migraine. A mechanism of hormonal interaction?]. ( Aschoff, JC, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (30.77) | 18.7374 |
| 1990's | 17 (32.69) | 18.2507 |
| 2000's | 14 (26.92) | 29.6817 |
| 2010's | 4 (7.69) | 24.3611 |
| 2020's | 1 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Foong, SC | 1 |
| Tan, ML | 1 |
| Foong, WC | 1 |
| Marasco, LA | 1 |
| Ho, JJ | 1 |
| Ong, JH | 1 |
| Vieira, ML | 2 |
| Dos Santos, AH | 1 |
| Silva, LS | 1 |
| Fernandes, GS | 1 |
| Kiss, AC | 2 |
| Moreira, EG | 1 |
| Mesquita, Sde F | 1 |
| Gerardin, DC | 2 |
| de Azevedo Camin, N | 1 |
| Montagnini, BG | 1 |
| Ishii, S | 1 |
| Ube, M | 1 |
| Okada, M | 1 |
| Adachi, T | 1 |
| Sugimoto, J | 1 |
| Inoue, Y | 1 |
| Uno, Y | 1 |
| Mutai, M | 1 |
| Minton, GO | 1 |
| Young, AH | 1 |
| McQuade, R | 1 |
| Fairchild, G | 1 |
| Ingram, CD | 1 |
| Gartside, SE | 1 |
| Lin, CC | 1 |
| Bai, YM | 1 |
| Wang, YC | 1 |
| Chen, TT | 1 |
| Lai, IC | 1 |
| Chen, JY | 1 |
| Chen, SY | 1 |
| Gau, SS | 1 |
| Liou, YJ | 1 |
| Vanattou-Saïfoudine, N | 1 |
| McNamara, R | 1 |
| Harkin, A | 1 |
| Korosue, K | 1 |
| Murase, H | 1 |
| Sato, F | 1 |
| Ishimaru, M | 1 |
| Harada, T | 1 |
| Watanabe, G | 1 |
| Taya, K | 1 |
| Nambo, Y | 1 |
| Martin, S | 1 |
| Lĵo, H | 1 |
| Peuskens, J | 3 |
| Thirumalai, S | 1 |
| Giudicelli, A | 1 |
| Fleurot, O | 2 |
| Rein, W | 2 |
| Baptista, T | 11 |
| Araujo de Baptista, E | 3 |
| Ying Kin, NM | 1 |
| Beaulieu, S | 3 |
| Walker, D | 1 |
| Joober, R | 2 |
| Lalonde, J | 2 |
| Richard, D | 2 |
| Zink, M | 1 |
| Knopf, U | 1 |
| Henn, FA | 1 |
| Thome, J | 1 |
| Sandstrom, MI | 1 |
| Nelson, CL | 1 |
| Bruno, JP | 1 |
| de Baptista, EA | 1 |
| Plamondon, J | 1 |
| Kin, NM | 1 |
| Rettenbacher, MA | 1 |
| Ebenbichler, C | 1 |
| Hofer, A | 1 |
| Kemmler, G | 1 |
| Baumgartner, S | 1 |
| Edlinger, M | 1 |
| Hummer, M | 1 |
| Lechleitner, M | 1 |
| Fleischhacker, WW | 1 |
| Bello, NT | 1 |
| Hajnal, A | 1 |
| De Hert, M | 1 |
| Mortimer, A | 1 |
| Zuo, J | 1 |
| Liu, Z | 1 |
| Ouyang, X | 1 |
| Liu, H | 1 |
| Hao, Y | 1 |
| Xu, L | 1 |
| Lu, XH | 1 |
| Vandereycken, W | 1 |
| Sannia, A | 1 |
| Benna, GM | 1 |
| Rupniak, NM | 2 |
| Mann, S | 1 |
| Hall, MD | 1 |
| Fleminger, S | 1 |
| Kilpatrick, G | 1 |
| Jenner, P | 2 |
| Marsden, CD | 2 |
| Fukaya, T | 1 |
| Furuhashi, N | 1 |
| Kono, H | 1 |
| Shinkawa, O | 1 |
| Takahashi, T | 1 |
| Suzuki, M | 1 |
| Rossi, F | 1 |
| Forgione, A | 1 |
| Seiler, N | 1 |
| Grauffel, C | 1 |
| Elands, J | 1 |
| van den Buuse, M | 1 |
| Knödgen, B | 1 |
| Sarhan, S | 1 |
| Moran, P | 1 |
| Gobaille, S | 1 |
| Holson, RR | 1 |
| Webb, PJ | 1 |
| Grafton, TF | 1 |
| Hansen, DK | 1 |
| Redmond, LM | 1 |
| Cross, DL | 1 |
| Strickland, JR | 1 |
| Kennedy, SW | 1 |
| Tozawa, H | 1 |
| Amiri, Z | 1 |
| Katz, Y | 1 |
| Weizman, A | 1 |
| Bidder, M | 1 |
| Snyder, SH | 1 |
| Gavish, M | 1 |
| Kirouac, GJ | 1 |
| Ganguly, PK | 1 |
| Matthews, K | 1 |
| Hall, FS | 1 |
| Wilkinson, LS | 1 |
| Robbins, TW | 2 |
| López, ME | 1 |
| Teneud, L | 1 |
| Contreras, Q | 2 |
| Alastre, T | 2 |
| de Quijada, M | 3 |
| Alternus, M | 1 |
| Weiss, SR | 1 |
| Musseo, E | 1 |
| Páez, X | 5 |
| Hernández, L | 7 |
| Martinez, JL | 2 |
| Molina, MG | 1 |
| Calanche de Cuesta, I | 1 |
| Acosta, A | 1 |
| Martinez, JM | 1 |
| Bech, P | 1 |
| Möller, HJ | 1 |
| Bale, R | 1 |
| Sato, T | 1 |
| Fetissov, SO | 1 |
| Meguid, MM | 1 |
| Miyata, G | 1 |
| Chen, C | 1 |
| Lacruz, A | 1 |
| Nagamachi, Y | 1 |
| Batrinos, ML | 1 |
| Pavlou, SN | 1 |
| Pitoulis, SA | 1 |
| Sfikaki, AP | 1 |
| Anousakis, C | 1 |
| Alexandrides, TK | 1 |
| Piaditis, GP | 1 |
| Aschoff, JC | 1 |
| Buvat, J | 1 |
| Decroix-Blacker, C | 1 |
| Legal, F | 1 |
| Gasnault, JP | 1 |
| Jones, GH | 1 |
| Hernandez, TD | 1 |
| Kendall, DA | 1 |
| Marsden, CA | 1 |
| Murzi, E | 2 |
| Burguera, JL | 1 |
| Burguera, M | 1 |
| Miyakawa, Z | 1 |
| Chiba, H | 1 |
| Hirato, K | 1 |
| Hosokawa, T | 1 |
| Ishizuka, Y | 1 |
| Yanaihara, T | 1 |
| Shimizu, H | 1 |
| Shimomura, Y | 1 |
| Uehara, Y | 1 |
| Kobayashi, I | 1 |
| Kobayashi, S | 1 |
| Halperin, R | 1 |
| Guerin, JJ | 1 |
| Davis, KL | 1 |
| Parada, MA | 2 |
| Puig de Parada, M | 1 |
| Parada, M | 1 |
| Barguño, JM | 1 |
| del Pozo, E | 1 |
| Cruz, M | 1 |
| Figueras, J | 1 |
| Prestwich, SA | 1 |
| Horton, RW | 1 |
| Dargent, D | 1 |
| Dumont, M | 1 |
| Malinas, Y | 1 |
| Gallioli, G | 1 |
| Grassi, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled Study of an Herbal Tea to Support Lactation[NCT02190448] | 60 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Metoclopramide to Aid Establishment of Breastfeeding After Delivery: a Randomized Controlled Trial[NCT00264719] | 160 participants (Anticipated) | Interventional | 2006-01-31 | Completed | |||
| Assessing the Feasibility of Testing Domperidone's Effect on Breastfeeding in Women With Insufficient Breast Milk: An RCT Pilot Study[NCT00284024] | Phase 2 | 45 participants (Anticipated) | Interventional | 2006-09-30 | Terminated (stopped due to Unable to recruit participants) | ||
| Efficacy of Herbal Galactogogues on Weight Gain of the Newborns Within the First Month of Life in Breastfeeding Mothers[NCT02740751] | 90 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | |||
| Metoclopramide to Improve Lactogenesis II in Diabetic Women: a Randomized Controlled Trial[NCT00477776] | Phase 3 | 160 participants (Anticipated) | Interventional | 2006-04-30 | Completed | ||
| Effect of Fenugreek on Milk Production[NCT00851591] | 3 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Low enrollment; investigator chose not to continue study) | |||
| Efficacy of Herbal Galactogogues: a Double-blinded, Placebo-controlled Randomized Trial.[NCT02233439] | 210 participants (Anticipated) | Interventional | 2014-09-30 | Not yet recruiting | |||
| Effect of Banana Blossom on Breast Milk Volume in Mothers of Preterm Newborns, a Randomized, Double Blinded, Placebo-controlled Trial[NCT05465460] | Phase 4 | 80 participants (Anticipated) | Interventional | 2022-07-09 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for sulpiride and Body Weight
| Article | Year |
|---|---|
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants.
Topics: Administration, Oral; Body Weight; Breast Feeding; Domperidone; Female; Galactogogues; Humans; Infan | 2020 |
Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
Topics: Adult; Amisulpride; Antipsychotic Agents; Body Weight; Clozapine; Dose-Response Relationship, Drug; | 2004 |
Pharmacotoxicological aspects of levosulpiride.
Topics: Animals; Body Weight; Digestive System; Dopamine Antagonists; Drug Evaluation, Preclinical; Eating; | 1995 |
Body weight gain induced by antipsychotic drugs: mechanisms and management.
Topics: Animals; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Endocrine System; Estr | 1999 |
8 trials available for sulpiride and Body Weight
| Article | Year |
|---|---|
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; B | 2002 |
Early changes of plasma lipids during treatment with atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; B | 2006 |
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weig | 2007 |
Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride.
Topics: Adult; Anorexia Nervosa; Body Weight; Clinical Trials as Topic; Double-Blind Method; Feeding Behavio | 1984 |
Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation.
Topics: Adult; Antipsychotic Agents; Body Weight; Endocrine System Diseases; Gonadal Steroid Hormones; Gonad | 1997 |
Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation.
Topics: Adult; Antipsychotic Agents; Body Weight; Endocrine System Diseases; Female; Glucose Tolerance Test; | 1997 |
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Body Weight; Double-Blind Method; Female; H | 1999 |
Failure of maintained hyperprolactinemia to improve lactational performance in late puerperium.
Topics: Adolescent; Adult; Body Weight; Female; Humans; Hyperprolactinemia; Infant, Newborn; Lactation; Post | 1988 |
40 other studies available for sulpiride and Body Weight
| Article | Year |
|---|---|
Lactational exposure to sulpiride: assessment of maternal care and reproductive and behavioral parameters of male rat pups.
Topics: Animals; Animals, Suckling; Body Weight; Dopamine Antagonists; Female; Lactation; Male; Maternal Beh | 2013 |
Effects of maternal exposure to the galactagogue Sulpiride on reproductive parameters in female rats.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Body Weight; Dose-Response Relationshi | 2015 |
Collaborative work on evaluation of ovarian toxicity. 17) Two- or four-week repeated-dose studies and fertility study of sulpiride in female rats.
Topics: Animals; Antipsychotic Agents; Body Weight; Drug Administration Schedule; Embryo, Mammalian; Embryon | 2009 |
Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder.
Topics: Adrenal Glands; Animals; Anti-Inflammatory Agents; Body Weight; Bupropion; Circadian Rhythm; Cortico | 2009 |
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Body Weight; Energy Metabolism; Female; Follow-Up Studies; | 2009 |
Caffeine promotes dopamine D1 receptor-mediated body temperature, heart rate and behavioural responses to MDMA ('ecstasy').
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Body Weight; Caffeine; Central Nervou | 2010 |
Successful induction of lactation in a barren Thoroughbred mare: growth of a foal raised on induced lactation and the corresponding maternal hormone profiles.
Topics: Aging; Animals; Body Weight; Estradiol; Female; Horses; Insemination, Artificial; Lactation; Pregnan | 2012 |
Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Body Composition; Body Weight; Corticosterone; Eating; | 2002 |
Neurochemical correlates of sparing from motor deficits in rats depleted of striatal dopamine as weanlings.
Topics: Age Factors; Animals; Body Weight; Brain Mapping; Corpus Striatum; Dopamine; Dopamine Antagonists; M | 2003 |
Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection.
Topics: Adipocytes; Adipose Tissue; Animals; Antipsychotic Agents; Body Composition; Body Weight; Cell Count | 2004 |
Acute methylphenidate treatments reduce sucrose intake in restricted-fed bingeing rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Weight; Bulimia; Central Nervous System Stimul | 2006 |
Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Brain; Conditioning, Psychological; Di | 2008 |
Prolactin response to stimulation in obesity.
Topics: Adult; Body Weight; Humans; Middle Aged; Obesity; Prolactin; Sulpiride; Thyrotropin-Releasing Hormon | 1983 |
Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat.
Topics: Acetylcholine; Animals; Apomorphine; Body Weight; Corpus Striatum; Haloperidol; Humans; Kinetics; Ma | 1984 |
The effect of sulpiride administration on maternal and fetal plasma prolactin levels, and fetal growth in rats.
Topics: Animals; Body Weight; Female; Fetal Blood; Fetus; Growth; Maternal-Fetal Exchange; Pregnancy; Prolac | 1983 |
Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Body Weight; Brain; Dyskinesia, Drug-Induced | 1995 |
Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzazepines; Body Weight; Brain; Dopamine D2 R | 1994 |
Efficacy of domperidone and sulpiride as treatments for fescue toxicosis in horses.
Topics: Animal Feed; Animals; Animals, Newborn; Body Weight; Domperidone; Estradiol; Female; Foodborne Disea | 1994 |
[The role of prolactin on sexual maturation of female rat].
Topics: Animals; Body Weight; Bromocriptine; Estradiol; Female; Organ Size; Ovary; Prolactin; Rats; Rats, Sp | 1993 |
Adrenal mitochondrial benzodiazepine receptors are sensitive to agents active at the dopamine receptor.
Topics: Adrenal Glands; Animals; Body Weight; Bromocriptine; Isoquinolines; Kidney; Male; Metoclopramide; Mi | 1993 |
Up-regulation of dopamine receptors in the brain of the spontaneously hypertensive rat: an autoradiographic analysis.
Topics: Animals; Autoradiography; Benzazepines; Blood Pressure; Body Weight; Brain Chemistry; Hypertension; | 1993 |
Retarded acquisition and reduced expression of conditioned locomotor activity in adult rats following repeated early maternal separation: effects of prefeeding, d-amphetamine, dopamine antagonists and clonidine.
Topics: Adrenergic alpha-Agonists; Amphetamine; Analysis of Variance; Animals; Anxiety, Separation; Behavior | 1996 |
Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates.
Topics: Amantadine; Animals; Antipsychotic Agents; Body Weight; Dopamine; Eating; Estrus; Female; Hypothalam | 1997 |
Intra-supraoptic nucleus sulpiride improves anorexia in tumor-bearing rats.
Topics: Animals; Anorexia; Body Weight; Dopamine Antagonists; Eating; Hypothalamus, Anterior; Male; Rats; Ra | 2001 |
The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?
Topics: Animals; Antipsychotic Agents; Body Weight; Dehydroepiandrosterone Sulfate; Dopamine; Dose-Response | 2002 |
Inhibitory effect of sulpiride on cinchophen gastric ulceration in dogs.
Topics: 11-Hydroxycorticosteroids; Animals; Behavior, Animal; Body Weight; Dogs; Drug Implants; Eating; Gast | 1977 |
Assessment of prolactin release in pituitary dwarfism with the sulpiride test.
Topics: Adolescent; Adult; Body Weight; Child; Diagnosis, Differential; Dwarfism, Pituitary; Humans; Male; P | 1978 |
[Sulpiride in the prevention of migraine. A mechanism of hormonal interaction?].
Topics: Adolescent; Adult; Body Weight; Female; Humans; Male; Menstruation Disturbances; Migraine Disorders; | 1977 |
[One thousand months of contraception with sulpiride].
Topics: Adolescent; Adult; Body Weight; Breast; Contraception; Drug Evaluation; Endometrium; Female; Galacto | 1976 |
Dopaminergic and serotonergic function following isolation rearing in rats: study of behavioural responses and postmortem and in vivo neurochemistry.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Weight; Brain Chemistry | 1992 |
Mechanism of the sex-dependent effect of lithium on body weight in rats.
Topics: Animals; Body Weight; Chlorides; Dose-Response Relationship, Drug; Drug Interactions; Female; Insuli | 1991 |
[Prolactin, ovarian and adrenal steroid hormone in relation to the vaginal opening in immature female rats].
Topics: Age Factors; Animals; Body Weight; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol | 1991 |
Involvement of sex hormone in body weight gain by selective D2 receptor antagonist sulpiride.
Topics: Animals; Body Weight; Estrogens; Feeding Behavior; Female; Gonadal Steroid Hormones; Male; Ovariecto | 1990 |
Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Clozapine; Corpus Striatum; Dopamine; | 1989 |
Mechanism of the body weight increase induced by systemic sulpiride.
Topics: Animals; Body Weight; Diestrus; Eating; Estradiol; Female; Male; Orchiectomy; Ovariectomy; Rats; Sul | 1989 |
Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?
Topics: Animals; Antipsychotic Agents; Body Weight; Bromocriptine; Dose-Response Relationship, Drug; Feeding | 1987 |
Puberty modifies sulpiride effects on body weight in rats.
Topics: Aging; Animals; Body Weight; Feeding Behavior; Female; Male; Rats; Rats, Inbred Strains; Sex Factors | 1988 |
Alterations in cerebral glutamic acid decarboxylase and 3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine.
Topics: Animals; Body Weight; Brain; Clozapine; Flunitrazepam; gamma-Aminobutyric Acid; Glutamate Decarboxyl | 1987 |
[Efficacy and clinical and biological tolerance of long-term veralipride administration. Apropos of 74 case reports].
Topics: Adult; Blood Chemical Analysis; Blood Pressure; Body Weight; Drug Evaluation; Female; Humans; Menopa | 1985 |
[Therapeutic activity of sulpiride in gastroduodenal ulcer].
Topics: Adult; Aged; Body Weight; Drug Evaluation; Drug Tolerance; Duodenal Ulcer; Female; Gastric Juice; Ga | 1974 |